Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARBOGEN: Carbogen + Phenylephrine for Progressing Stroke
NCT06770426Phase 3Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Feb 2025
- Primary completion
- Sep 2027
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carbogen in ischemic stroke (2 arms), sponsored by Yonsei University. Primary endpoints: percent improvement of NIHSS score at 24 hours, difference of NIHSS score at 24 hours and 4 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
carbogen
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06770426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770426.